ProCE Banner Activity


PARP Inhibitors as Precision Medicine in Metastatic Prostate Cancer

PCE On Demand Live Presentation

The treatment armamentarium for progressive, metastatic castrate-resistant prostate cancer (mCRPC) now includes the FDA-approved poly (ADP-ribose) polymerase (PARP) inhibitors olaparib and rucaparib. In this activity, an advanced practice provider reviews how to identify patients most likely to benefit from PARP inhibitor–based therapy. The case-based discussion illustrates treatment decision points and management of treatment-related adverse events, with a focus on shared decision-making and patient education to enhance patient quality of life during treatment.

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Released: January 30, 2023

Expiration: January 29, 2024

No longer available for credit.



Terran W. Sims

Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN

Nurse Practitioner
Department of Urology
University of Virginia
Charlottesville, Virginia

Sarah Traverso

Sarah Traverso, MMS, PA-C

Physician Assistant
Division of Genitourinary Oncology
Northwestern Medicine
Chicago, Illinois

Provided by

ProCE Banner


This activity is supported by educational grants from


Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.

Target Audience

Oncology NPs, PAs, and nurses

Learning Objectives

After completing this activity, participants should be better able to:

  • Summarize the appropriate use of PARP inhibitors in mCRPC according to guideline recommendations and clinical trial data

  • Apply recommended strategies to monitor for and manage adverse events associated with PARP inhibitors 

  • Integrate patient education and feedback to optimize patient experiences during treatment and survivorship


All faculty and planners participating in continuing education activities sponsored by Partners for Advancing Clinical Education (PACE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PACE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Terran Sims, MSN, ACNP-C, CNN, COCN-C: consultant/advisor/speaker: Cololast Corp USA.

Sarah Traverso, MMS, PA-C, has no relevant financial relationships to disclose.

The planners and content peer reviewers from Partners for Advancing Clinical Education and Practicing Clinicians Exchange, do not have any relevant financial relationships to disclose.

Instructions for Credit

Learners wishing to earn CE/CME credit must:

  • View the content in its entirety
  • Relate the content material to the learning objective
  • Complete evaluation form

The estimated time to complete this activity is 1 hour.


This program has been made available online.


The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Partners for Advancing Clinical Education, Practicing Clinicians Exchange, or any educational supporter.


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


ANCC Credit Designation
Nursing contact hours: 1.0, which includes 1.0 hours of pharmacology credit 


AAPA Credit Designation
Joint AccreditationPartners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until January 10, 2024. PAs should only claim credit commensurate with the extent of their participation.


IPCE Credit Designation  

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.